Discover 98 paid clinical trials in Great Falls, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 98
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Great Falls MT, Anaconda MT, Missoula MT, Kalispell MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase2, Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: Great Falls MT, Anaconda MT, Missoula MT, Kalispell MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06672146
Phase2, Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,
Location: Great Falls MT, Anaconda MT, Missoula MT, Kalispell MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06498635
Phase3, Recruiting
Multi-Institutional Registry for Prostate Cancer Radiosurgery
for
Prostate Cancer Early Risk Treated by Radiosurgery,
Location: Great Falls MT, Missoula MT, Billings MT, Spokane Valley WA,
Sponsor: RPCR, Inc.
Sex: Male
Age: 18 - 70+
Code: NCT01226004
Recruiting
Evaluating SUI-100Γäó, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
for
Stress Urinary Incontinence (SUI)
Location: Great Falls MT, Boise ID, Las Vegas NV, Phoenix AZ, Wichita KS,
Sponsor: Acoustic Wave Cell Therapy, Inc.
Sex: Female
Age: 22 - 70+
Code: NCT06862648
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
By submitting, you consent to the use of your personal details, including contact information and location, to respond to your request for information related to clinical trials, as outlined in the Privacy Policy. If at any time you want to discontinue receiving alerts, please click the Unsubscribe link in the email received.
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
for
Metastatic Malignant Neoplasm in the Bone,
Location: Great Falls MT, Havre MT, Bozeman MT, Missoula MT,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06745024
Phase3, Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy